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Abstract
Purpose: Matrix metalloproteases (MMPs) are tissue-remodeling enzymes
that function during the remodeling process, such as in immune-inflammatory
diseases. Metalloprotease-2 (MMP-2) and metalloprotease-9 (MMP-9) are
gelatinases that degrade several types of extracellular matrix collagen. It is
hypothesized that in temporomandibular joint (TMJ) dysfunction, MMP-2 and
MMP-9 expression levels may be elevated. Therefore, the objective of this
study is to determine the association of MMP-2 and MMP-9 expression with
temporomandibular joint dysfunction using an immunohistochemical approach
to evaluate the joint disk.
Material and Methods: A total of 45 human temporomandibular joint
samples were collected, with 36 samples in the test group (patients with
anterior disk displacement with reduction (n = 29) and without reduction
(n = 7)) and nine samples in the control group. The immunostaining of the
TMJ disks was statistically compared between the groups (P < 0.05).
Results: There was a statistically significant difference for the area of MMP-2
immunostaining between the control group and the displacement disks with
reduction group (ADDwR) (P = 0.048) and between the groups with disk
displacement and without reduction (ADDwoR) (P = 0.029). The expression of
MMP-2 was significantly elevated in the ADDwoR group.
Conclusion: No statistically significant difference was found between the
variable area of MMP-9 expression in the disk with and without disk
displacement, as determined by immunohistochemical analysis. However,
there was an elevation of MMP-2 expression in the disks of patients with
displacement and without reduction (more severe alteration).
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Introduction
The temporomandibular joint (TMJ) is a bilateral joint that
adapts and remodels according to functional demands. The fibrous
cartilaginous disk in the TMJ consists of regularly arranged collagen
fibers and fibroblast-like cells. It plays an important role in distributing
the pressure loads of articular surfaces of the condyle and glenoid
fossa during joint movements.1 When the disk is overloaded and
exceeds its remodeling capability, it may suffer structural changes,
such as the fragmentation of compact collagen fibers or an alteration
of synovial cells, which cover the disk and are responsible for its
lubrication and can lead to TMJ disorders.2 The pathogenesis of TMJ
dysfunction is multifactorial, but the early identification of the major
contributing factor is critical for improved treatment outcomes. Of the
TMJ dysfunctions that may lead to disk degeneration, anterior disc
displacement is generally observed in TMJ patients3 and often precedes
osseous remodeling, disk perforation, and osteoarthritic changes.4
The inflammatory process is a coordinated response against
trauma and infection. However, when the initiating inflammatory agent
is not removed, this physiological response may lead to pathological
conditions. Matrix metalloproteinases (MMPs), a family of 20
proteolytic enzymes that degrade all types of collagen, proteoglycans,
and other components of extracellular matrix are among the enzymes
found in the physiological and inflammatory tissue environments.5
Their activity is essential for remodeling and adapting cartilage and
other tissues.6 The tissue inhibitors of metalloproteinases (TIMPs) work
together with the MMPs during physiological alterations,7 but under
inflammatory conditions, the excess activity and overexpression of
MMPs results in tissue destruction. The MMPs are divided into the
following subgroups: collagenases (MMP-1, MMP-8, and MMP-13) that
degrade fibrillar collagen types I, II, and III; stromelysins (MMP-3 and
MMP-11) that degrade proteoglycans and non-helical regions of
collagens; and gelatinases (MMP-2 and MMP-9), which degrade the
specific collagen types I, IV, V, and XI.8
MMP-2 and MMP-9 are produced primarily by inflammatory cells,
and their expression is regulated at the transcriptional level by
inflammatory mediators, such as interleukin-1.9 MMP-2 and MMP-9 are
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synthesized as latent proenzymes, which are cleaved and activated
outside the cells. MMP-2 and MMP-9 are increased in the serum and
synovial fluids of arthritic patients and are considered markers of
arthritis and are also associated with cartilage degradation in animal
experiments.10 MMP-2 was detected in early-stage osteoarthritis
patients, whereas MMP-9 was highly expressed in patients with
anterior disk displacement without reduction and advanced
osteoarthritis.11 However, the sample was collected from synovial fluid,
and the state of disk degradation was unknown during at that time. To
better understand the progressive stage of the disease, it is important
to acquire a detailed clinical evaluation and knowledge of the TMJ
degenerating mechanisms.12
Although the involvement of several MMPs in TMJ dysfunction is
known, little has been reported regarding which MMP enzymes are
involved in the TMJ disk disarrangements, and the elucidation of this
relationship may contribute to improved diagnosis and treatment of
TMJ patients. The majority of studies have been performed with
synovial fluid,13 animal models,13,14 or cadavers.15 However, MMP-2
and MMP-9 expressions have not been studied in the degenerated
disks of human TMJ patients. Therefore, the objective of this study is
to determine the association of MMP-2 and MMP-9 expressions in the
disks of patients with temporomandibular joint dysfunction using an
immunohistochemical approach to evaluate the joint disk.

Materials and methods
Sample selection
The sample set comprised 45 disk specimens (Table 1) from 33
patients, male and female, with a mean age of 32.36 years (17–57). A
total of 36 TMJ displaced disk specimens were collected from patients
treated between 2002 and 2009 at the Evangelic University Hospital of
Curitiba, Brazil. Nine virtually unaffected human TMJ disks were
evaluated with the pathological material. The study was approved by
the Ethical Committee on Research at Pontifical Catholic University of
Paraná, Brazil, according to Resolution 196/96 of the National Health
Council and approved under registration number 104.
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Table 1. Baseline clinical characteristics of the study group with and without
TMJ dysfunction
Patient
(n = 33)

Race

Sex

Age
Diagnoses
Affected Affected side
(years)
side (Right)
(Left)

1. ADDwoR, anterior disk displacement without reduction; ADDwR, anterior disk
displacement with reduction; C FX, condylar fracture; CH, condylar
hyperplasia.
1

Caucasian

Female 35

DDwoR

2

Caucasian

Female 24

DDwoR

3

Caucasian

Female 23

DDwoR

X

4

Caucasian

Female 45

DDwoR

X

5

Caucasian

Female 32

DDwoR

X

6

Caucasian

Female 30

ADDwR

X

7

AfroAmerican

Female 20

ADDwR

X

8

AfroAmerican

Female 57

ADDwR

X

9

Caucasian

Female 33

ADDwR

X

10

Caucasian

Female 25

ADDwR

X

X

11

Caucasian

Female 22

ADDwR

X

X

12

Caucasian

Female 42

ADDwR

X

13

Caucasian

Female 56

ADDwR

X

14

Caucasian

Female 26

ADDwR

X

X

15

Caucasian

Female 38

ADDwR

X

X

16

Caucasian

Female 37

ADDwR

X

X

17

Caucasian

Female 36

ADDwR

X

X

18

Caucasian

Female 34

ADDwR

19

Caucasian

Female 46

ADDwR

X

X

20

Caucasian

Female 26

ADDwR

X

X

21

Caucasian

Female 30

ADDwR

X

X

22

Caucasian

Female 36

ADDwR

X

23

Caucasian

Female 44

ADDwR

X

24

Caucasian

Female 26

ADDwR

X

25

Caucasian

Female 17

CH

X

26

Caucasian

Female 43

C FX

X

27

Caucasian

Female 40

CH

X

28

Caucasian

Female 18

CH

29

Caucasian

Male

C FX

30

Caucasian

Female 30

CH

31

AfroAmerican

Male

26

CH

X

32

Caucasian

Male

27

C FX

X

33

Caucasian

Male

18

C FX

26

X

X
X
X

X

X

X
X
X

X
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The subjects did not have any of the following: use of
orthodontic appliances; chronic usage of anti-inflammatory drugs;
history of diabetes, hepatitis, or HIV infection; immunosuppressive
chemotherapy; history of any disease known to severely compromise
immune function; current pregnancy or lactation; dentofacial
deformity; major jaw trauma; previous TMJ surgery; and previous
steroid injection in the TMJ. The subjects completed personal medical
history questionnaires and, within a protocol approved by an
Institutional Review Board, signed a consent form after being advised
of the nature of the study. All patients were asked to complete a pain
questionnaire, and an experienced oral and maxillofacial surgeon
performed a clinical examination. The clinical examination consisted of
palpating the TMJ region, noting the occurrence of painful
opening/closing of the mouth, and listening for crepitation. The
patients considered affected were treated surgically when they
presented painful clinical signs of disk displacement after unsuccessful
non-surgical treatment for at least 6 months. Patients presenting with
pain related to muscular spasms were not included in this study. For
the complementary exams, all patients received a panorex. These
patients were from the Brazilian public health system; therefore, very
few patients had the financial means to afford other exams, such as
computerized tomography (CT) scan or a TMJ magnetic resonance
imaging.
Accordingly, the diagnoses were primarily clinical. The subjects
were included in clinical categories, according to the presence or
absence of disk displacement.
1. Test group: composed of 36 samples, and all patients were
diagnosed with one of the two following TMJ dysfunctions: (i)
disk displacement with reduction (ADDwR, n = 29) or (ii) disk
displacement without reduction (ADDwoR, n = 7). ADDwoR is
considered the more severe condition.
2. Control group (n = 9): composed of patients with no signs or
symptoms of TMJ dysfunction, such as pain or mouth opening
limitation. Of the control patients, four individuals presented
condyle fractures (CFx) confirmed by radiographs and CT scans
and needed surgery for fracture reduction, and five subjects
displayed active condyle hyperplasia (CH). Therefore, a wedge
of the posterior region of the disks of all subjects was removed
to physiologically adapt the disk on the condyle head.
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MMP-2 and MMP-9 immunohistochemical analysis
The TMJ disk sections were deparaffinized with xylol
(2 × 10 min) and rehydrated with absolute ethyl alcohol (3 × 1 min)
and 80% ethyl alcohol (1 × 1 min).
Endogenous peroxidase activity was quenched by treatment
with H2O2 (5% in methanol) for 10 min. Target Retrieval Solution™
(Dako, DK-2600 Glostrup, Denmark) was used prior to slide staining
for heat-inducing epitope retrieval for formalin-fixed, paraffinembedded material, according to the manufacturer's instructions.
The sections were incubated with monoclonal MMP-2 and MMP-9
antibodies (Novocastra, New Castle, UK) diluted 1:50 in phosphatebuffered saline (PBS) and 0.1% bovine serum albumin (BSA). These
monoclonal antibodies only stain a cellular fraction of MMP-2 and MMP9.
For negative controls, the primary antibody was not added, and
PBS was used instead. The secondary antibody Advance™ (Dako, DK2600 Glostrup, Denmark) was applied for 30 min, according to the
manufacturer's instructions.
The immunoreactions were visualized by incubating the sections
with 1 drop 3,3′ diaminobenzidine (DAB) chromogen (OriGene,
Rockville, MD, USA) in 1 ml distilled water. The sections were lightly
counterstained with Harris hematoxylin for 5 min and finally mounted.
The immunostaining was considered specific to MMP-2 and MMP-9
because immunoreactivity was not observed in the negative controls.
The positive areas were marked using the color morphometry
method, which consisted of an analysis of the anti-MMP-2 and MMP-9
reaction area with the TMJ disk tissue. For this purpose, images of
consecutive fields were captured with a 40× objective lens coupled to
a BX50 Olympus microscope with a Sony camera (Model DXC-107A),
and image analysis was performed with Image Pro Plus software
(Media Cybernetics Inc., Silver Spring, MD, USA). This software allows
an observer to select and paint the positive areas to obtain an image
model and make a mask for staining the other slides. A single blinded
observer performed this procedure. Moreover, the software
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automatically calculates the area of the positive reaction. The data
were entered into a spreadsheet, and Microsoft Excel (Redmond, WA,
USA) was used for the statistical analysis. The variable area was
measured in square micrometers (μm2) and was obtained with the
mean of all positive areas.

Statistical analysis
SPSS version 14.0 (SPSS Institute, Inc., Chicago, IL, USA) was
used for the statistical analyses. To analyze the area and density, the
average of the results from all available samples of each patient was
considered. Descriptive statistical values are presented as the mean
and standard deviation, median, minimum, and maximum.
Comparisons of the three groups were performed with one-way
analysis of variance (ANOVA) and LSD (least significant difference) for
multiple comparisons. To achieve the symmetric condition, the data
were previously submitted to a logarithmic transformation. A value of
P < 0.05 indicates statistical significance.

Results
MMP-2 expression analysis
A significant difference was found between the groups with and
without TMJ dysfunction (P = 0.030) for the MMP-2 area of expression
(Table 2). There was increased MMP-2 immunostaining in the ADDwR
group compared with the control group (P = 0.048). There was an
increased level of expression in the ADDwoR group compared with the
ADDwR group (P = 0.029; Table 2).
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Table 2. Analysis of MMP-2 expression area between the groups
Variable

Group

n Media Median Minimum Maximum

Standard
deviation

P-valuea

1. CG, control group; ADDwoR, disk displacement without reduction; ADDwR,
disk displacement with reduction.
2. a One-way ANOVA, P < 0.05 Area: CG × ADDwR: P = 0.048; CG × ADDwoR:
P = 0.725; ADDwR × ADDwoR: P = 0.029.
Area
(μm2)

CG

9

ADDwR

29 16.16 15.18

ADDwoR 7

23.11 16.61
28.98 26.15

14.15

39.14

9.55

7.90

31.28

5.77

6.68

58.05

19.09

0.030

MMP-9 expression analysis
Comparison of the control and affected groups with or without
reduction showed no significant difference for the MMP-9 area of
immunostaining (P = 0.476; Table 3).
Table 3. Analysis of MMP-9 expression area between the groups
Variable Group

n Media Median Minimum Maximum

Standard
deviation

P-valuea

1. CG, control group; ADDwoR, disk displacement without reduction; ADDwR,
disk displacement with reduction.
2. a One-way ANOVA, P < 0.05.
Area
(μm2)

CG

9 21.2

15.8

6.8

53.9

15.7

ADDwR

31 18.1

16.1

2.1

102.6

17.6

ADDwoR 7 29.5

21.8

6.8

101.3

32.8

0.476

Discussion
The articular disk of human in the TMJ adapts and remodels
when subjected to loading. When the loading pressure reaches a high
level, the inflammatory process is initiated and may entail the
degradation and replacement of the natural matrix by abnormal
tissue.16 The upregulation of some MMPs has been observed in
pathological conditions in the TMJ synovial fluid, resulting in tissue
destruction, and MMPs are considered the primary enzymes involved in
matrix turnover.15,17-20 MMP gene polymorphisms have been associated
with temporomandibular joint degeneration,21 whereas MMP-9 gene
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promoter polymorphisms were associated with degenerative diseases,
such as arthritis and atherosclerosis.22
MMP-2 and MMP-9 expressions are regulated by several growth
factors, such as platelet derived growth factor, tumor necrosis factor α,
and interleukin-1. The latent presence of MMP-2 has been identified in
healthy joints and is produced by fibroblasts, whereas MMP-9 is
produced in large quantities by inflammatory cells, particularly in
patients with osteoarthritis.11 Both MMP-2 and MMP-9 are hypothesized
to play multiple roles in TMJ pathogenesis because MMP-2 activates
MMP-13 and because increased expression of MMP-2, concomitant with
MMP-9, was observed in pathological conditions.2,21 However, studies
of these two enzymes have been performed in either animal models,
cadavers, or the synovial fluid of human pathological TMJ. To the best
of our knowledge, this is the first study to investigate the presence of
MMP-2 and MMP-9 in human temporomandibular disks.
Our results showed statistically significant differences between
CG and ADDwR and between ADDwoR and ADDwR. Notably, the
expression of MMP-2 was also significantly increased in the disk
displacement without reduction group compared with the disk
displacement with reduction group and the control group. No
difference was observed between the control group and ADDwoR.
Although the lack of difference may be due to the small sample size
and high variability in the expression of MMP-2 in these groups, it may
also indicate the association of the increased expression of MMP-2 with
a more severe TMJ disorder. The MMP-9 analysis showed no
statistically significant difference between the groups in relation to the
area of expression. The results of this study differ from the results of
Yoshida et al.11 who found higher levels of MMP-9 in the synovial fluid
in advanced TMJ disease. Moreover, the lack of difference between the
groups may be related to the small number of individuals and the high
variability of MMP-9 expression within each group. Another possible
explanation is that there may be a difference between MMP-9
expression in the synovial fluid and the disks during TMJ dysfunction.
It is notable that although the sample size is reduced, only
approximately 5% of people worldwide present a functional or
pathological TMJ condition amenable to surgery,23 and for ethical
reasons, it is not possible to retrieve healthy retrodiscal tissue from
normal patients to serve as controls. Moreover, the absence of MMP
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expression between the groups may be because the control group
consisted of disks from patients with condyle fracture. However, for
the controls presenting with mandibular condyle fracture, the surgical
procedure occurred up to 24 h after the trauma, which diminishes the
action of MMP degradation in the area. For the controls with
hyperplasia, because hyperplasia is restricted to the condyle, this
condition does not appear to affect the articular disk.
Although the sample size is small, to the best of our knowledge,
this study has the largest sample of disks from living people, as
opposed to disks from cadavers or from animals. Moreover, for human
cadavers, no previous clinical records were available, which made it
impossible to determine whether the subjects presented with any
inflammatory degenerative alterations.
With an increasing number of patients presenting with TMJ
dysfunction, the identification of the disease stage is a priority for
directing proper treatment. In this study, increased expression of
MMP-2 was observed in patients with disk displacement without
reduction by immunohistochemistry analysis. No statistically significant
difference was found in the area of expression of MMP-9, possibly
because of the high interindividual variation in its expression, which
therefore requires a larger number of individuals to determine whether
the level of this protease is increased in the disks of individuals with
TMJ dysfunction.
Future analyses of other MMPs combined with the results of this
study may contribute to a better understanding of the role of MMPs on
tissue remodeling and destruction. These studies may also improve the
understanding of TMJ dysfunction and lead to improved patient
treatments.
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